173 related articles for article (PubMed ID: 18996188)
1. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation.
Handoko A; Ian L; Peter SJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):265-74. PubMed ID: 18996188
[TBL] [Abstract][Full Text] [Related]
2. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
Adi H; Larson I; Stewart PJ
Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
[TBL] [Abstract][Full Text] [Related]
3. Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation.
Adi H; Larson I; Chiou H; Young P; Traini D; Stewart P
Pharm Res; 2006 Nov; 23(11):2556-65. PubMed ID: 16972185
[TBL] [Abstract][Full Text] [Related]
4. Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios.
Adi H; Larson I; Chiou H; Young P; Traini D; Stewart P
J Pharm Sci; 2008 Aug; 97(8):3140-52. PubMed ID: 18023007
[TBL] [Abstract][Full Text] [Related]
5. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures.
Islam N; Stewart P; Larson I; Hartley P
J Pharm Sci; 2004 Apr; 93(4):1030-8. PubMed ID: 14999738
[TBL] [Abstract][Full Text] [Related]
6. Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation.
Das S; Larson I; Young P; Stewart P
J Pharm Sci; 2009 Mar; 98(3):1015-27. PubMed ID: 18661537
[TBL] [Abstract][Full Text] [Related]
7. Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity.
Das S; Larson I; Young P; Stewart P
Eur J Pharm Sci; 2009 Jun; 37(3-4):442-50. PubMed ID: 19491036
[TBL] [Abstract][Full Text] [Related]
8. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?
Islam N; Stewart P; Larson I; Hartley P
Pharm Res; 2004 Mar; 21(3):492-9. PubMed ID: 15070101
[TBL] [Abstract][Full Text] [Related]
9. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
10. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
11. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
Murnane D; Martin GP; Marriott C
J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
[TBL] [Abstract][Full Text] [Related]
12. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography.
Tong HH; Shekunov BY; York P; Chow AH
J Pharm Sci; 2006 Jan; 95(1):228-33. PubMed ID: 16315225
[TBL] [Abstract][Full Text] [Related]
13. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
[TBL] [Abstract][Full Text] [Related]
14. The production of 'aerodynamically equivalent' drug and excipient inhalable powders using a novel fractionation technique.
Taki M; Marriott C; Zeng XM; Martin GP
Eur J Pharm Biopharm; 2011 Feb; 77(2):283-96. PubMed ID: 21185373
[TBL] [Abstract][Full Text] [Related]
15. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
16. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
Zeng XM; Pandhal KH; Martin GP
Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
[TBL] [Abstract][Full Text] [Related]
17. Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH.
Das S; Larson I; Young P; Stewart P
Eur J Pharm Sci; 2009 Nov; 38(4):347-54. PubMed ID: 19732829
[TBL] [Abstract][Full Text] [Related]
18. Effect of milling and sieving on functionality of dry powder inhalation products.
Steckel H; Markefka P; teWierik H; Kammelar R
Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
[TBL] [Abstract][Full Text] [Related]
19. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery.
Dhumal RS; Biradar SV; Paradkar AR; York P
Int J Pharm; 2009 Feb; 368(1-2):129-37. PubMed ID: 18996462
[TBL] [Abstract][Full Text] [Related]
20. Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization.
Murnane D; Marriott C; Martin GP
Eur J Pharm Biopharm; 2008 May; 69(1):94-105. PubMed ID: 17981448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
